Sarma Katrapati, MD
Internal Medicine · Toledo, OHNPI 1467485227
Payments from drug & device makers
Across 261 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$677
- AstraZeneca$397
- GSK$329
- Pfizer$320
- Novo Nordisk$300
- Merck$205
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,271100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $677 |
| AstraZeneca | 18 | $397 |
| GSK | 14 | $329 |
| Pfizer | 19 | $320 |
| Novo Nordisk | 22 | $300 |
| Merck | 14 | $205 |
| Amgen(2 entities) | 12 | $191 |
| Boehringer Ingelheim | 11 | $191 |
| Astellas Pharma US Inc | 10 | $139 |
| Sanofi-aventis U.S. LLC | 9 | $133 |
| Alkermes, Inc. | 6 | $120 |
| Novartis | 7 | $119 |
| Sunovion Pharmaceuticals Inc. | 8 | $118 |
| Amarin Pharma, Inc. | 8 | $117 |
| Axsome Therapeutics, Inc. | 4 | $116 |
| Bayer | 5 | $92 |
| Lilly USA, LLC | 5 | $76 |
| Exact Sciences | 4 | $72 |
| Johnson & Johnson | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $63 |
| Abbott | 4 | $61 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Dexcom, Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Bausch Health US, LLC | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Gilead | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Lifescan, Inc. | 1 | $12 |
How this compares
$4,277 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $108,272 |
| EliquisApixaban | 101 | $91,590 |
| JanuviaSitagliptin Phosphate | 71 | $64,616 |
| TradjentaLinagliptin | 76 | $51,596 |
| VraylarCariprazine Hcl | 24 | $50,368 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $48,034 |
| JardianceEmpagliflozin | 40 | $41,389 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $35,868 |
| MounjaroTirzepatide | 23 | $34,962 |
| XareltoRivaroxaban | 22 | $34,613 |
| FarxigaDapagliflozin Propanediol | 47 | $31,327 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $19,911 |
| MyrbetriqMirabegron | 25 | $17,477 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $15,778 |
| TrintellixVortioxetine Hydrobromide | 11 | $15,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $300 | $108,27272 claims |
| MerckJanuvia, Janumet, Dulera | $205 | $107,439119 claims |
| Boehringer IngelheimTradjenta, Jardiance | $191 | $92,985116 claims |
| PfizerEliquis | $320 | $91,590101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $329 | $82,50594 claims |
| AbbVieVraylar, Linzess | $677 | $60,03137 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $397 | $57,15695 claims |
| Lilly USA, LLCMounjaro | $76 | $34,96223 claims |
| Johnson & JohnsonXarelto | $66 | $34,61322 claims |
| Astellas Pharma US IncMyrbetriq | $139 | $17,47725 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $63 | $15,31811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Toledo
- Srini HejeebuToledo$410K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.